Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Stoke Therapeutics, Inc. , a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that management will present at the ...

Strong evidence for ALS often comes from familial forms of the disease, where specific gene mutations— for example in the ...

BioCryst Pharmaceuticals stock climbs 9% on strong Orladeyo sales, 2025 revenue guidance boost, and market dominance. See why ...

The increasing occurrence of genetic disorders is a major factor fueling the demand for oligonucleotide synthesis, as these molecules are essential for gene therapies and diagnostics aimed at ...

Neurofilament light (NFL) is a powerful and sensitive biomarker for tracking neuronal health and disease progression.

Warfarin was associated with more risk than apixaban (Eliquis; 55.38 vs 21.42 per 1,000 person-years, HR 2.60, 95% CI ...

Eli Lilly kicks off 2025 with key licensing deals and M&A, boosting its position across therapeutic areas amid rising drug ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

William Blair issued their Q1 2026 earnings per share (EPS) estimates for Ionis Pharmaceuticals in a report released on Wednesday, February 19th. William Blair analyst M. Minter forecasts that the ...

PESHAWAR (Pajhwok): The Awami National Party (ANP) says Pakhtuns are bearing the brunt of terrorism due to flawed policies of ...

The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...